230 related articles for article (PubMed ID: 37467967)
1. Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances.
Chao A; Wu RC; Lin CY; Chang TC; Lai CH
Biomed J; 2023 Oct; 46(5):100633. PubMed ID: 37467967
[TBL] [Abstract][Full Text] [Related]
2. Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix.
Paterniti TA; Dorr K; Ullah A; White J; Williams H; Ghamande S
Obstet Gynecol; 2021 Nov; 138(5):813-816. PubMed ID: 34619736
[TBL] [Abstract][Full Text] [Related]
3. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
4. Development of an improved diagnostic nomogram for preoperative prediction of small cell neuroendocrine cancer of the cervix.
Li YZ; Liu P; Mao BH; Wang LL; Ren JL; Xu YS; Liu GY; Xin ZH; Lei JQ
Br J Radiol; 2022 Dec; 95(1140):20220368. PubMed ID: 36169239
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors of Surgically Treated Early-Stage Small Cell Neuroendocrine Carcinoma of the Cervix.
Yuan L; Jiang H; Lu Y; Guo SW; Liu X
Int J Gynecol Cancer; 2015 Sep; 25(7):1315-21. PubMed ID: 26186071
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
[TBL] [Abstract][Full Text] [Related]
9. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
10. Mixed mucinous adenocarcinoma/large cell neuroendocrine carcinoma of the uterine cervix: case report and molecular characterization of a rare entity.
Fattorini C; Rocca BJ; Giusti A; Arganini M; Perotti B; Cavazzana A; Ambrosio MR; Volante M
Virchows Arch; 2024 Jan; 484(1):141-146. PubMed ID: 36988712
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine carcinoma of the uterine cervix: A clinicopathologic retrospective study of 31 cases with prognostic implications.
Wang KL; Yang YC; Wang TY; Chen JR; Chen TC; Chen HS; Su TH; Wang KG
J Chemother; 2006 Apr; 18(2):209-16. PubMed ID: 16736891
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
Miyoshi AI; Ueda Y; Kurita T; Kimura T; Yoshino K
Anticancer Res; 2023 Apr; 43(4):1397-1405. PubMed ID: 36974776
[TBL] [Abstract][Full Text] [Related]
13. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
Wang VE; Urisman A; Albacker L; Ali S; Miller V; Aggarwal R; Jablons D
J Immunother Cancer; 2017 Sep; 5(1):75. PubMed ID: 28923100
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
17. Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases.
Ordulu Z; Mino-Kenudson M; Young RH; Van de Vijver K; Zannoni GF; Félix A; Burandt E; Wong A; Nardi V; Oliva E
Am J Surg Pathol; 2022 Dec; 46(12):1670-1681. PubMed ID: 36069807
[TBL] [Abstract][Full Text] [Related]
18. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract][Full Text] [Related]
19. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
[TBL] [Abstract][Full Text] [Related]
20. [Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer].
Zhang SY; Wang Y
Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):98-103. PubMed ID: 33472320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
